ADC Therapeutics
VerifiedDevelops proprietary antibody drugs targeting cancer
Launch date
Employees
Ownership
Market cap
$616m
Net debt
-
Firm valuation
$1.7b (Public information from Apr 2021)
Share price
$8.02 ADCT
Lausanne Canton of Vaud (HQ)
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | 5m | 4m | 4m | - | - | - | - |
| % growth | - | (20 %) | - | - | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
* | N/A | Corporate spinout | |
| $50m | Series A | ||
| $40m | Early VC | ||
| $80m | Growth Equity VC | ||
| $105m | Growth Equity VC | ||
* | $200m | Series E | |
| N/A | $76m | Series E | |
| N/A | $25m | Series E | |
* | N/A | $268m Valuation: $1.3b | IPO |
| Total Funding | $576m | ||
Recent News about ADC Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.